Blog

Wild baboon microbiome offers clues to healthy aging: Researchers working with wild baboons in East Africa used microbiome data from fecal samples to develop a gut-based biological aging clock, which they used to predict chronological age with an error rate of two (2) years, outperforming human-based versions. This animal model revealed that age-related shifts in microbial diversity are influenced by sex, social status, and environmental conditions, and the findings, reported in eLife, may help scientists better understand how manipulating the microbiome can promote healthy aging in humans.

Analysis reveals medical device professionals are putting in over a quarter (1/4) more working hours than the average American — the equivalent of 69 extra workdays annually.

Peanut allergies and the search for a cure: Peanut allergies, once rare, have become a major public health challenge since the 1990s, affecting millions of children and adults and reshaping daily life in schools and homes. The causes remain unclear, with theories pointing to overly clean environments, genetics and delayed childhood exposure. A true cure is not yet available; however, new therapies such as oral immunotherapy, skin patches, biologic drugs like Xolair, immune resetting regimens and early peanut introduction in infants offer families real hope for safety and a future with fewer restrictions.

The Supreme Court has ruled that the Trump administration can proceed with cutting $783 million in research funding as part of its efforts to reduce federal diversity, equity and inclusion initiatives. The decision, made by a 5-4 vote, lifts a previous block on these cuts, although future funding cuts under the same directive remain blocked. The ruling has sparked criticism from Democratic state attorneys general and public health groups, who argue that it disrupts scientific research and potential breakthroughs. The Justice Department supports the cuts, arguing that funding decisions should not be subject to judicial review.

MD+DI (Medical Device and Diagnostic Industry) Senior Editor Point of View (POV) geeks out over the pop star’s MedTech comments during Swift’s recent appearance on the New Heights podcast

Trump Finds New Way to Tariff Medtech: The Trump Administration has launched a Section 232 investigation into imported medical devices, targeting cardiovascular, diabetes, and imaging equipment for national security concerns.

Apple snail’s eye regeneration could aid human therapy: A study in Nature Communications has found that golden apple snails have the ability to regrow their eyes, in a process that shares anatomical and genetic similarities with humans. Researchers using CRISPR-Cas9 to study gene function during regeneration found that genes such as pax6 are crucial for eye development. The research could lead to therapies for vision loss in humans by activating dormant regenerative genes.

Researcher challenges grant cuts: Pulmonologist Neeta Thakur, a Researcher at the University of California, San Francisco, is leading a legal challenge against the federal government’s suspension of grants for research deemed to have a diversity, equity, and inclusion component. Thakur’s research on wildfire smoke and its impacts on underserved communities was disrupted by the funding cuts; however, she won a preliminary injunction and the grants were temporarily reinstated.

Trump’s autism initiative touts a little-tested vitamin as treatment: As part of a highly anticipated announcement in which U.S. President Donald Trump outlined his administration’s approach to what he called the “crisis of autism,” federal officials said the Food and Drug Administration (FDA) would approve a drug called leucovorin, a form of folate, as “the first FDA-recognized treatment pathway for autism” — an unusual move for a pill only tested in a few small studies.

First patient gets CRISPR-edited insulin cells in diabetes trial: A Swedish man with type 1 diabetes became the first person to receive CRISPR-edited pancreatic cells that produce insulin while avoiding immune rejection, allowing the cells to survive for at least three (3) months without the need for immunosuppressive drugs, according to a study in The New England Journal of Medicine. Developed by Sana Biotechnology, these cells had key immune-stimulating proteins removed and were enhanced with a protective protein, CD47, using CRISPR technology.